Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?

Alemtuzumab (Campath-1H) has been widely used for T-cell depletion following both conventional and reduced-intensity conditioning allografts. We studied the impact of alemtuzumab used in vivo and in vitro on infections, immune reconstitution, and allograft outcome. The use of alemtuzumab in vivo fol...

תיאור מלא

מידע ביבליוגרפי
Main Authors:	Chakrabarti, S, Hale, G, Waldmann, H
פורמט:	Journal article
שפה:	English
יצא לאור:	2004

פריטים דומים

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
מאת: Watson, C, et al.
יצא לאור: (2004)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
מאת: Hale, G, et al.
יצא לאור: (2002)

The evolving role of alemtuzumab (Campath-1H) in renal transplantation
מאת: Phuong-Thu T Pham, et al.
יצא לאור: (2008-12-01)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
מאת: Hale, G, et al.
יצא לאור: (1988)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
מאת: Clatworthy, MR, et al.
יצא לאור: (2009)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
מאת: Watson, C, et al.
יצא לאור: (2005)

Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.
מאת: Potter, M, et al.
יצא לאור: (2000)

Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go
מאת: Lv Meng, et al.
יצא לאור: (2012-03-01)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
מאת: Fibbe, W, et al.
יצא לאור: (1993)

CAMPATH-1 antibodies in stem-cell transplantation.
מאת: Hale, G, et al.
יצא לאור: (2001)

Where do we go from here?
מאת: Rai, Vijesh
יצא לאור: (2016)

Expert Systems: Where Are We? And Where Do We Go from Here?
מאת: Davis, et al.
יצא לאור: (2004)

Editorial: Where Are We Now and Where Do We Go From Here
מאת: Gabriele Manganaro
יצא לאור: (2022-01-01)

Availability of Campath-1 antibodies for bone marrow transplantation.
מאת: Hale, G, et al.
יצא לאור: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
מאת: Hale, G, et al.
יצא לאור: (1994)

Alemtuzumab (Campath-1H) para tratamento da leucemia linfóide crônica
מאת: Maria Kadma da Silva Carriço, et al.
יצא לאור: (2003-06-01)

Tractography: where do we go from here?
מאת: Jbabdi, S, et al.
יצא לאור: (2011)

Afterword: Where Do We Go from Here?
מאת: Kimberly Vinall, et al.
יצא לאור: (2017-01-01)

Transplantation tolerance: the big picture. Where do we stand, where should we go?
מאת: Waldmann, H
יצא לאור: (2017)

Allogeneic stem cell transplantation for lymphoproliferative disease using BEAM-Campath conditioning: An effective regime with low procedure-related toxicity.
מאת: Cull, G, et al.
יצא לאור: (1999)

Commentary: Retinoblastoma management–Where are we and where do we go from here?
מאת: P Mahesh Shanmugam
יצא לאור: (2020-01-01)

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
מאת: Lundin, J, et al.
יצא לאור: (2001)

How Did We Get Here and Where are We Going?
מאת: Georgina CHAMBERS
יצא לאור: (2022-09-01)

Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.
מאת: Russell, N, et al.
יצא לאור: (1999)

CAMPATH-1H in inflammatory arthritis.
מאת: Watts, R, et al.
יצא לאור: (1993)

COVID-19 - where do we go from here?
מאת: Lee, Pei Hua, et al.
יצא לאור: (2020)

Propriospinal myoclonus: where do we go from here?
מאת: Brown, P
יצא לאור: (2014)

Oil prices : where do we go from here?/
מאת: 284295 Zanoyan, Vahan
יצא לאור: (1986)

Math anxiety : where do we go from here? /
מאת: 297422 Hunt, Glen E.

Advanced ceramics : where do we go from here?/
מאת: 348668 Smith, Vincent, et al.

Multiple Sclerosis: Where do we go from here?
מאת: Marta Tejera-Alhambra, et al.
יצא לאור: (2016-07-01)

Calibration research: Where do we go from here?
מאת: Linda eBol, et al.
יצא לאור: (2012-07-01)

PITUITARY INCIDENTALOMAS – WHERE DO WE GO FROM HERE?
מאת: Syed Ali Imran
יצא לאור: (2016-08-01)

Developmental Dyslexia: Where Do We Go from Here?
מאת: Paul E. Engelhardt
יצא לאור: (2020-03-01)

OMR At Crossroads; Where Do We Go From Here ?
מאת: Mangala Meti
יצא לאור: (2004-01-01)

Topological photonics: Where do we go from here?
מאת: Segev Mordechai, et al.
יצא לאור: (2020-10-01)

T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival.
מאת: Chakrabarti, S, et al.
יצא לאור: (2003)

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
מאת: Kottaridis, P, et al.
יצא לאור: (2001)

CAMPATH: from concept to clinic.
מאת: Waldmann, H, et al.
יצא לאור: (2005)

Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
מאת: Cull, G, et al.
יצא לאור: (2000)